CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 21 No. 1
Pages: 1  2  
Next
BOOK REVIEW 

Hematology-Oncology Therapy

January 1, 2007

Authors:
MICHAEL M. BOYIADZIS, MD, MHSc
PETER F. LEBOWITZ, MD, PhD
JAMES N. FRAME, MD
TITO FOJO, MD, PhD, et al
Publisher:
McGraw-Hill, New York
899 pages
Price: $69.00

Reviewed by
THOMAS J. SAPHNER, MD, FACP
Principal Investigator
St. Vincent Regional Community Clinical
Oncology Program
Green Bay Oncology Clinic
St. Mary's Hospital
Medical Center
Green Bay, Wisconsin

This up-to-date, concise text is well suited to experienced practitioners who need good information fast. The text's 899 pages are well researched, demonstrating the efforts of 4 major authors and 89 contributing authors. Information is integrated from the oncology and hematology literature, practice guidelines, and the experience of the authors.

The book's 67 chapters cover oncologic and nonneoplastic hematology disorders as well as supportive care. Chapters 1 through 38 address common cancers; chapters 39 through 55 address supportive care, drug preparation, complications, and screening; and chapters 56 through 67 cover selected noncancer hematologic diseases.

The oncology chapters cover 38 cancers in a very standardized format. Common cancers such as breast, lung, colon, and prostate are covered as well as less common cancers such as carcinoid tumors, adrenocortical cancer, and pheochromocytoma. Each oncology chapter addresses epidemiology, pathology, survival, work-up, staging, caveats, and regimens. The section on caveats is the most readable and most interesting. The real value of the book is the presentation of treatment regimens in a standardized format. Each treatment regimen is accompanied by references, a description of the regimen, the patient population studied, efficacy, toxicity, and dose modifications. Nearly 500 regimens are included.

The first of 16 supportive care chapters covers nausea and vomiting, including tables categorizing the level of nausea caused by each drug and the appropriate regimen for that level. One chapter is allocated to the preparation and administration of each chemotherapeutic agent, while another discusses dose modifications. Additional chapters in this section describe the use of growth factors and bisphosphonates. Common day-to-day issues, including extravasations, catheter-related infections, venous clots, and neutropenic fevers, are also covered.

The 12 chapters on selected hematologic diseases are well suited to the medical oncologist who is consulted about nonmalignant hematology problems. Chapters include discussions of von Willebrand disease, hemophilia, heparin(Drug information on heparin)-induced thrombocytopenia, aplastic anemia, and idiopathic thrombocytopenic purpura. Three hematologic malignancies are also included—polycythemia vera, essential thrombocythemia, and myelodysplastic syndromes.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy